Literature DB >> 204206

The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations.

R B Tesh.   

Abstract

The prevalence of encephalomyocarditis virus (EMC) antibodies among selected human populations in various regions of the world was determined by the plaque reduction neutralization method. Antibody rates among children ranged from 1.0 to 33.9%, while those among adults varied from 3.2 to 50.6%. No differences between sexes were found in the frequency of EMC infection. The pattern of age-specific antibody rates observed among the study populations suggests that EMC infection occurs primarily during childhood. There appeared to be no association between the presence of EMC antibodies and potential exposure to rats. Sera from diabetic, suspected encephalitis, and myocarditis patients were also examined for EMC neutralizing antibodies. The prevalence of antibodies among these groups was not significantly different from that of control populations in the same geographic regions. No association was demonstrated between EMC infection and these three diseases. The results of this study indicate that EMC infection in man is fairly common but that most human cases are probably asymptomatic and/or unrecognized.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 204206     DOI: 10.4269/ajtmh.1978.27.144

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Porcine encephalomyocarditis virus persists in pig myocardium and infects human myocardial cells.

Authors:  L A Brewer; H C Lwamba; M P Murtaugh; A C Palmenberg; C Brown; M K Njenga
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Attenuated Mengo virus: a new vector for live recombinant vaccines.

Authors:  R Altmeyer; M Girard; S van der Werf; V Mimic; L Seigneur; M F Saron
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  Identification and characterization of the cell surface 70-kilodalton sialoglycoprotein(s) as a candidate receptor for encephalomyocarditis virus on human nucleated cells.

Authors:  Y M Jin; I U Pardoe; A T Burness; T I Michalak
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Enzyme-linked immunosorbent assay for immunoglobulin G antibody to encephalomyocarditis virus.

Authors:  J D Shanley
Journal:  J Clin Microbiol       Date:  1980-11       Impact factor: 5.948

5.  Adaptation of Saffold virus 2 for high-titer growth in mammalian cells.

Authors:  Shannon Hertzler; Zhiguo Liang; Balint Treso; Howard L Lipton
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Evaluation of a duplex reverse-transcription real-time PCR assay for the detection of encephalomyocarditis virus.

Authors:  Shaomin Qin; Darren Underwood; Luke Driver; Carol Kistler; Ibrahim Diallo; Peter D Kirkland
Journal:  J Vet Diagn Invest       Date:  2018-06-02       Impact factor: 1.279

Review 7.  The encephalomyocarditis virus.

Authors:  Margot Carocci; Labib Bakkali-Kassimi
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

8.  MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.

Authors:  Autumn J Ruiz; Elizabeth M Hadac; Rebecca A Nace; Stephen J Russell
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

9.  Isolation and Characterization of Encephalomyocarditis Virus from Dogs in China.

Authors:  Ya-Kun Luo; Lin Liang; Qing-Hai Tang; Ling Zhou; Li-Jun Shi; Ying-Ying Cong; Wen-Cheng Lin; Shang-Jin Cui
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

10.  Human febrile illness caused by encephalomyocarditis virus infection, Peru.

Authors:  M Steven Oberste; Eduardo Gotuzzo; Patrick Blair; W Allan Nix; Thomas G Ksiazek; James A Comer; Pierre Rollin; Cynthia S Goldsmith; James Olson; Tadeusz J Kochel
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.